BioSpace News Archive

Spero Therapeutics, Inc. announced that on January 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 16,000 restricted stock unit awards to two new employees under the Spero Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc. will webcast management participation.

Poseida Therapeutics, Inc. announced that Eric Ostertag, M.D., Ph.D., has resigned as Executive Chairman and will retire from the Board of Directors effective February 3, 2023.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company’s Chief Financial Officer (CFO), effective February 1, 2023.

SRI International, an independent nonprofit research institute behind countless cutting-edge technological advances, announced the promotion of Kathlynn Brown to President of its Biosciences Division.

LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

GeneDx Holdings Corp. announced the closing of its previously announced underwritten public offering of shares of its Class A common stock and concurrent registered direct offering of shares of its Class A common stock.

Dynavax Technologies Corporation announced that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol “DVAX”.

Bruker Corporation announced it will report fourth quarter and fiscal year 2022 financial results before market opening on Thursday, February 9, 2023.

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP test to aid in the diagnosis of CHF across Europe.